Stay updated on Quizartinib-Decitabine-Venetoclax Combo in AML Clinical Trial
Sign up to get notified when there's something new on the Quizartinib-Decitabine-Venetoclax Combo in AML Clinical Trial page.

Latest updates to the Quizartinib-Decitabine-Venetoclax Combo in AML Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.3%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe web page has been updated to reflect a new version, changing from v2.14.4 to v2.15.0.SummaryDifference1.0%
- Check30 days agoChange DetectedThe web page has been updated to a new version (v2.14.4) as of April 2, 2025, replacing the previous version (v2.14.3) from March 25, 2025).SummaryDifference1.0%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check80 days agoChange DetectedThe page has updated the treatment options for Acute Myeloid Leukemia and Myelodysplastic Syndrome, changing the relevant date from October 28, 2024, to February 10, 2025.SummaryDifference0.9%
- Check87 days agoChange DetectedThe webpage now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference6%
Stay in the know with updates to Quizartinib-Decitabine-Venetoclax Combo in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Quizartinib-Decitabine-Venetoclax Combo in AML Clinical Trial page.